Literature DB >> 10791618

Biochemical bone turnover markers in patients with ankylosing spondylitis.

N Yilmaz1, J Ozaslan.   

Abstract

In this study, bone formation markers [alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BALP) and osteocalcin (BGP)] and bone resorption markers [pyridinium cross-links: pyridinoline (Pyd) and deoxypyridinoline (Dpyd)] were studied in 44 patients with ankylosing spondylitis (AS) and in a control group of 41 subjects. The AS group was classified according to duration of disease, erythrocyte sedimentation rate (ESR) values and gender. Urinary Pyd and Dpyd concentrations of the patients were higher than in the control group, concomitant with the lower T-score values of the patients in both the anteroposterior lumbar spine and femoral neck. Although a correlation between markers of disease activity [ESR and C-reactive protein (CRP)] and bone turnover markers was not observed, urinary excretion of Dpyd and Pyd was enhanced in the ESR >20 mm/h subgroup compared with the ESR < or =20 mm/h subgroup. A significant elevation of urinary Dpyd was also observed in the female subgroup and long disease duration subgroup. Serum ALP, BALP and BGP levels of the patients and control group were not statistically different (p>0.05). No significant differences were observed between mineral and calcitropic hormone levels in either group, and total testosterone levels of the patients were within the reference range. According to this study, urinary Pyd levels are elevated in patients with AS. Gender, duration of disease and ESR also have an impact on urinary excretion of these collagen compounds. It can be concluded that bone turnover in patients with AS reflects normal osteoblastic activity and high osteoclastic activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791618     DOI: 10.1007/s100670050024

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

Review 1.  Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?

Authors:  M M Ward
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 2.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 3.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

4.  Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis.

Authors:  Abdellah El Maghraoui; Saida Tellal; Souad Chaouir; Khalil Lebbar; Ahmed Bezza; Abderrazak Nouijai; Lahsen Achemlal; Sanaa Bouhssain; El Mostapha Derouiche
Journal:  Clin Rheumatol       Date:  2004-12-08       Impact factor: 2.980

5.  Osteoporosis in ankylosing spondylitis.

Authors:  Marina Magrey; Muhammad Asim Khan
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

6.  Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS).

Authors:  Barbara Ruaro; Andrea Casabella; Sabrina Paolino; Carmen Pizzorni; Massimo Ghio; Chiara Seriolo; Luigi Molfetta; Patrizio Odetti; Vanessa Smith; Maurizio Cutolo
Journal:  Clin Rheumatol       Date:  2018-10-06       Impact factor: 2.980

Review 7.  Bone Involvement in Patients with Spondyloarthropathies.

Authors:  Willem Lems; Corinne Miceli-Richard; Judith Haschka; Andrea Giusti; Gitte Lund Chistensen; Roland Kocijan; Nicolas Rosine; Niklas Rye Jørgensen; Gerolamo Bianchi; Christian Roux
Journal:  Calcif Tissue Int       Date:  2022-01-23       Impact factor: 4.333

8.  The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis.

Authors:  S Arends; A Spoorenberg; G A W Bruyn; P M Houtman; M K Leijsma; C G M Kallenberg; E Brouwer; E van der Veer
Journal:  Osteoporos Int       Date:  2010-07-06       Impact factor: 4.507

9.  Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Zhongchao Fu; Zhizhong Ye
Journal:  Arch Rheumatol       Date:  2016-04-15       Impact factor: 1.472

10.  Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

Authors:  S Visvanathan; D van der Heijde; A Deodhar; C Wagner; D G Baker; J Han; J Braun
Journal:  Ann Rheum Dis       Date:  2008-05-21       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.